Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Oct 21, 2020

Chugai Enters into a License Agreement for Chugai’s Antibody Engineering Technologies with Novo Nordisk

TOKYO, October 21, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that it has entered into a license agreement for worldwide non-exclusive rights of several Chugai’s antibody engineering technologies with Novo Nordisk A/S.

Under the terms of agreement, Novo Nordisk will receive the rights to use several Chugai’s antibody engineering technologies for their research activities and optional rights for the development and marketing of therapeutic antibodies applying those technologies. In return for the license, Chugai will receive a fee for technology access. In case Novo Nordisk creates a candidate antibody and exercises optional rights, Chugai will receive an upfront payment, milestone payments according to the development status, and royalty payment if the compound is launched as an approved antibody drug.

“Antibody engineering technology is one of Chugai’s core competencies and has led to the creation of innovative antibody drugs,” said Dr. Junichi Nezu, Chugai’s Vice President, Head of Research Division. “We have high hopes that Novo Nordisk will utilize Chugai’s proprietary antibody engineering technologies to solve unmet medical needs and create novel medicines.”

“With this agreement we have secured long-term access to antibody engineering technologies from Chugai which is one of the world leading companies within this field” added Lars Fogh Iversen, Senior Vice President, Global Research Technologies, Novo Nordisk. “Novo Nordisk is committed to protein-based therapeutics and access to premier technologies is essential to advancing the highest quality therapeutic programs.”

About Chugai
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs.
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english/. 

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,500 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com. 

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top